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Dynamic modulation of phosphoprotein
expression in ovarian cancer xenograft
models
Antonis Koussounadis1, Simon P. Langdon2, Inhwa Um2,3, Charlene Kay2, Kyle E. Francis2, David J. Harrison3
and V. Anne Smith1*
Abstract
Background: The dynamic changes that occur in protein expression after treatment of a cancer in vivo are poorly
described. In this study we measure the effect of chemotherapy over time on the expression of a panel of proteins
in ovarian cancer xenograft models. The objective was to identify phosphoprotein and other protein changes
indicative of pathway activation that might link with drug response.
Methods: Two xenograft models, platinum-responsive OV1002 and platinum-unresponsive HOX424, were used.
Treatments were carboplatin and carboplatin-paclitaxel. Expression of 49 proteins over 14 days post treatment
was measured by quantitative immunofluorescence and analysed by AQUA.
Results: Carboplatin treatment in the platinum-sensitive OV1002 model triggered up-regulation of cell cycle, mTOR
and DDR pathways, while at late time points WNT, invasion, EMT and MAPK pathways were modulated. Estrogen
receptor-alpha (ESR1) and ERBB pathways were down-regulated early, within 24 h from treatment administration.
Combined carboplatin-paclitaxel treatment triggered a more extensive response in the OV1002 model modulating
expression of 23 of 49 proteins. Therefore the cell cycle and DDR pathways showed similar or more pronounced
changes than with carboplatin alone. In addition to expression of pS6 and pERK increasing, components of the AKT
pathway were modulated with pAKT increasing while its regulator PTEN was down-regulated early. WNT signaling,
EMT and invasion markers were modulated at later time points. Additional pathways were also observed with
the NFκB and JAK/STAT pathways being up-regulated. ESR1 was down-regulated as was HER4, while further
protein members of the ERBB pathway were upregulated late. By contrast, in the carboplatin-unresponsive
HOX 424 xenograft, carboplatin only modulated expression of MLH1 while carboplatin-paclitaxel treatment
modulated ESR1 and pMET.
Conclusions: Thirteen proteins were modulated by carboplatin and a more robust set of changes by carboplatin-
paclitaxel. Early changes included DDR and cell cycle regulatory proteins associating with tumor volume changes,
as expected. Changes in ESR1 and ERBB signaling were also observed. Late changes included components of MAPK
signaling, EMT and invasion markers and coincided in time with reversal in tumor volume reduction. These results
suggest potential therapeutic roles for inhibitors of such pathways that may prolong chemotherapeutic effects.
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Background
Ovarian cancer is a leading cause of gynecologic cancer
mortality worldwide. Platinum-based drugs, often com-
bined with a taxane, are the main chemotherapy treat-
ment that follows surgical debulking [1]. Although the
majority of patients initially respond to this treatment,
around 70 % relapse and present with recurrent disease
between 6 and 24 months [2]. The overall 5-year survival
is around 30 % [3], highlighting the need for improved
patient targeting with appropriate treatment. Many
treated chemo-resistant patients (30 %) suffer serious
side effects needlessly, while their outcomes could be
improved by guiding such patients to alternative therap-
ies. Characterisation of the dynamic processes involved
in response to chemotherapy in ovarian cancer models
may help develop tools for the prediction of chemo-
response and outcome and help identify key molecular
changes occurring on treatment.
Cancer is the result of alterations in a limited number
of pathways [4]. Recent genomic analyses of ovarian can-
cer have identified several deregulated pathways [5, 6].
For instance cell cycle associated defects are a hallmark
of many cancer types including ovarian cancer [7]. Ovar-
ian cancer is characterised by dysregulation of multiple
cellular signaling pathways involved in cancer initiation
and progression, such as EGFR/ERBB [8], MAPK [9],
PI3K/AKT/mTOR [6, 10], WNT [11], JAK/STAT [12],
NFκB [13], ERα [14]. Hypoxic response promotes inva-
siveness by inducing tumor migration and metastasis
[15], while SNAIL [16], AKT, EGFR [17] and WNT
pathway [18] mediate epithelial-to-mesenchymal (EMT)
transition. Several DNA repair pathways, such as ataxia-
telangiectasia-mutated (ATM) [19], Fanconi anemia (FA)
[20], nucleotide excision repair (NER) pathways [21], are
activated in response to platinum-induced DNA damage.
A number of these pathways have been associated with
chemo-resistance [22], while oncogenic pathway profiles
have been associated with clinical outcome [23].
BRCA1/2 mutation status is also informative with re-
spect to platinum response [24].
Activation states of cell signaling pathways can be
inferred by measuring expression of representative
proteins or phosphoproteins [25]. Quantitative prote-
omic approaches allow for the estimation of expres-
sion of multiple proteins in a large number of
samples and have been used in ovarian cancer to
identify factors associated with platinum response and
to characterise histotype-dependent protein expression
[26, 27]. Measurement of multiple proteins over time
may reveal dynamic expression patterns of several
pathways simultaneously. Clustering tumors according
to activation patterns of oncogenic pathways can
identify disease relevant deregulation patterns and
support molecular classification [28].
In an earlier study, we analysed genome-wide dy-
namic gene expression changes in ovarian cancer
models after chemotherapy treatment [29]. We ob-
served deregulated DNA repair, cell cycle and apop-
tosis pathways and identified gene sets associated
with survival [28]. Here we measured the dynamic ef-
fect of carboplatin and paclitaxel chemotherapy on
the expression of a combined panel of 49 proteins
and phosphoproteins using the same xenograft
models. The models had distinct histological origin
and diverse response patterns to carboplatin. As in
the gene expression study, protein expression was
assessed over a period of 14 days after treatment with
drugs with concurrent monitoring of tumor volume.
The selected proteins are frequently aberrant or be-
long to oncogenic pathways often deregulated in ovar-
ian cancer [6, 30]. The targeted proteomics approach
allowed the simultaneous detection of dynamic onco-
genic pathway activation at the protein level in re-
sponse to treatment, thus providing a complementary
aspect to the transcriptomics study. We identified
time-related changes in activated oncogenic pathways
and we analysed those in respect to tumor volume
reduction.
Methods
Xenograft dataset
The platinum sensitive OV1002 ovarian cancer xeno-
graft model was derived from a high grade serous adeno-
carcinoma, while the HOX424 xenograft model was of
clear cell/endometrioid origin and had reduced respon-
siveness to platinum. Both cell lines were established at
the Institute of Genetics and Molecular Medicine,
University of Edinburgh as described previously [31].
Ovarian tumor fragments were implanted subcutane-
ously into adult (12 week old) female CD-1 nu/nu mice
and were allowed to grow to 4–6 mm in diameter in
negative pressure isolators (La Calhene, Cambridge,
UK). Mice were then stratified into treatment groups
such that mean tumor volumes were equivalent across
the groups. Tumor size was monitored twice weekly and
relative tumor volumes (RTV) were calculated for each
individual tumor by dividing the tumor volume on day t
(Vt) by the tumor volume on day 0 (V0). Mice were
grouped into three groups: untreated controls, carbopla-
tin treated (50 mg/kg) and carboplatin (50 mg/kg) +
paclitaxel treated (10 mg/kg). Treatment was adminis-
tered as a single intraperitoneal dose on day 0. Groups
of both treated and untreated control mice were sacri-
ficed on Day 1, 2, 4, 7 and 14 after treatment. Tumors
were placed into formalin, fixed and paraffin embedded.
Tissue sections were cut and stained with a range of
antibodies as described below against 49 protein targets
(Table 1). The xenograft dataset consisted of 99 OV1002
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Table 1 Protein targets
Entrez Gene ID Gene symbol Protein (phospho-protein) Gene name Function
1017 CDK2 CDK2, pCDK2 cyclin-dependent kinase 2 CELL CYCLE
891 CCNB1 CyclinB1 cyclin B1 CELL CYCLE
595 CCND1 CyclinD1 cyclin D1 CELL CYCLE
4609 MYC Myc v-myc myelocytomatosis viral oncogene homolog
(avian)
CELL CYCLE
1026 CDKN1A P21 cyclin-dependent kinase inhibitor 1A (p21, Cip1) CELL CYCLE
1027 CDKN1B P27 cyclin-dependent kinase inhibitor 1B (p27, Kip1) CELL CYCLE
5925 RB1 pRb retinoblastoma 1 CELL CYCLE
672 BRCA1 BRCA1, pBRCA1 breast cancer 1, early onset DNA DAMAGE REPAIR
2067 ERCC1 ERCC1 excision repair cross-complementing rodent repair
deficiency, complementation group 1
DNA DAMAGE REPAIR
4292 MLH1 MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2
(E. coli)
DNA DAMAGE REPAIR
4436 MSH2 MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1
(E. coli)
DNA DAMAGE REPAIR
2956 MSH6 MSH6 mutS homolog 6 (E. coli) DNA DAMAGE REPAIR
1111 CHEK1 pChk1 CHK1 checkpoint homolog (S. pombe) DNA DAMAGE REPAIR
3014 H2AFX pH2AX H2A histone family, member X DNA DAMAGE REPAIR
3021 H3F3B pHH3 H3 histone, family 3B (H3.3B) DNA DAMAGE REPAIR
5395 PMS2 PMS2 PMS2 postmeiotic segregation increased 2
(S. cerevisiae)
DNA DAMAGE REPAIR
7157 TP53 pP53 tumor protein p53 DNA DAMAGE REPAIR
8202 NCOA3 AIB1 nuclear receptor coactivator 3 GROWTH SIGNALING:
MAPK signaling
207 AKT1 AKT, pAKT v-akt murine thymoma viral oncogene homolog 1 GROWTH SIGNALING:
PI3K/AKT signaling
1499 CTNNB1 BCatenin, pBCatenin catenin (cadherin-associated protein), beta 1, 88 kDa GROWTH SIGNALING:
Wnt signaling
1956 EGFR EGFR epidermal growth factor receptor (erythroblastic
leukemia viral (v-erb-b) oncogene homolog, avian)
GROWTH SIGNALING:
ERBB signaling
2099 ESR1 ER,pER estrogen receptor 1 GROWTH SIGNALING:
ESR signaling
5594 MAPK1 ERK, pERK mitogen-activated protein kinase 1 GROWTH SIGNALING:
MAPK signaling
2064 ERBB2 HER2 v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2, neuro/glioblastoma derived oncogene
homolog (avian)
GROWTH SIGNALING:
ERBB signaling
2065 ERBB3 HER3 v-erb-b2 erythroblastic leukemia viral oncogene
homolog 3 (avian)
GROWTH SIGNALING:
ERBB signaling
2066 ERBB4 HER4 v-erb-a erythroblastic leukemia viral oncogene
homolog 4 (avian)
GROWTH SIGNALING:
ERBB signaling
3486 IGFBP3 IGFBP3 insulin-like growth factor binding protein 3 GROWTH SIGNALING:
IGF signaling
3488 IGFBP5 IGFBP5 insulin-like growth factor binding protein 5 GROWTH SIGNALING:
IGF signaling
6194 RPS6 S6, pS6 ribosomal protein S6 GROWTH SIGNALING:
mTOR signaling, hypoxia
5241 PGR PgR progesterone receptor GROWTH SIGNALING:
PI3K/AKT signaling
5604 MAP2K1 pMEK mitogen-activated protein kinase kinase 1 GROWTH SIGNALING:
MAPK signaling
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and 67 HOX424 xenograft samples. Phenotypic and raw
data are shown in Additional file 1. There were 3–8 bio-
logical replicates at each time point and treatment, ex-
cept at day 2 for HOX424, where there were 2 and 1
replicates for each treatment. Agreement between sample
expression levels was good as measured by the correlation
coefficients (r) among replicates of each condition (mean r
0.94, 95 % confidence interval 0.934–0.955, Additional file
2, column E). The xenograft studies were undertaken
under a UK Home Office Project Licence in accordance
with the Animals (Scientific Procedures) Act 1986 and
studies were approved by the University of Edinburgh
Animal Ethics Committee.
Protein expression
Protein expression was measured by immunofluores-
cence using methods previously described [25]. Tissue
microarrays were prepared from xenograft material that
had been formalin-fixed at the time of collection and
had been processed into paraffin blocks. Microarray
slides were deparaffinized and antigen-retrieved by
pressure-cooking. Endogenous peroxidases were blocked
with 2.5 % hydrogen peroxide for 15 min and non-
specific binding blocked with serum-free protein block
for 15 min. Slides were then incubated with primary
antibodies (Table 2) with AE1/AE3 mouse monoclonal
cytokeratin antibody at room temperature for 1 h. After
washing, sections were incubated for 1 h at room
temperature with secondary antibodies, which included
an Alexa 555-conjugated goat anti-mouse antibody
diluted 1:100, and prediluted goat anti-rabbit antibody
conjugated to a horseradish peroxidase decorated
dextran-polymer backbone (EnVision, Dako). Slides were
then incubated for 10 min with Cy5-tyramide, which is ac-
tivated by horseradish peroxidase, to visualise target
protein expression. 4', 6-Diamidino-2-phenylindole (DAPI;
Molecular Probes, Eugene, Ore) was used to stain the nu-
clear compartment. For analysis, pan-cytokeratin anti-
body was used to identify tumor cells and normal
epithelial cells, DAPI counterstain to identify nuclei,
and Cy-5-tyramide detection for target protein in
compartmentalised (tissue and subcellular) analysis of
tissue sections. Monochromatic images of each
0.6 mm TMA core were captured at 20× objective
using an Olympus AX-51 epifluorescence microscope,
and high-resolution digital images analysed by the
AQUAnalysis software. AQUA scores, which represent
the sum of the Cy5-tyramide score for the target pro-
tein divided by the area of the cellular compartment
(cytoplasm or nucleus), were then generated for each
sample. A detailed description of the AQUA analysis
has been reported elsewhere [32].
Protein expression analysis and statistics
AQUA scores were log-transformed averaged from repli-
cate cores. Means of differentially expressed proteins log
fold change values for each time point were hierarchic-
ally clustered using Cluster 3.0 in order to identify
significant proteins with similar temporal expression
profiles. Heatmaps were visualized using TreeView [33].
Bioconductor package limma [34] was used for differen-
tial expression calculations. Significant genes had FDR
adjusted p-values below 0.05. Treated samples were con-
trasted to pooled untreated control from all time points
in each xenograft. Differentially expressed proteins were
classified as expressed early (Days 1–4) or late (Days 7,
14), and transient (expressed significantly in 1 time
point) or continuous (expressed significantly at least 2
continuous time points).
Table 1 Protein targets (Continued)
4790 NFKB1 pNFkB nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
GROWTH SIGNALING:
NFkB signaling
6774 STAT3 pSTAT3 signal transducer and activator of transcription 3 GROWTH SIGNALING:
Jak/STAT signaling
5728 PTEN PTEN phosphatase and tensin homolog GROWTH SIGNALING:
PI3K/AKT signaling
1366 CLDN7 Claudin7 claudin 7 ETM/INVASION
999 CDH1 Ecadherin cadherin 1, type 1, E-cadherin (epithelial) ETM/INVASION
3091 HIF1A HIF1alpha hypoxia inducible factor 1, alpha subunit ETM/INVASION
4233 MET MET, pMET met proto-oncogene ETM/INVASION
5054 SERPINE1 PAI serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1
ETM/INVASION
6615 SNAI1 Snail snail homolog 1 (Drosophila) ETM/INVASION
7431 VIM Vimentin vimentin ETM/INVASION
Details and function of 49 protein form targets (41 proteins) and their pathways tested in the xenograft protein expression experiment. There were 16
phosphorylated proteins, 8 of which were tested for both phosphorylated and unphosphorylated forms
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Results
Carboplatin dynamically activates phosphoproteins in
ovarian cancer xenografts
Protein candidates were selected from pathways identi-
fied in a recent analysis of somatic mutations and copy
number changes in ovarian cancer [5] and known path-
ways of interest in this disease [25]. A total of 49 protein
forms were investigated which are known to be involved
in DDR (BRCA1/pBRCA1, ERCC1, MLH1, MSH2,
MSH6, pCHK1, pH2AX, PHH3, PMS2, pP53), cell cycle
regulation (CDK2/pCDK2, Cyclin B, Cyclin D1, MYC,
p21, p27, pRb), EMT/invasion (Claudin 7, E-cadherin,
HIF1α, MET/pMET, PAI1, SNAIL, Vimentin) and growth
signaling including WNT (CTNNB1/pCTNNB1), PI3K/
AKT (AKT/pAKT, PTEN), mTOR (S6/pS6), NFκB
(NFκB1), MAPK (ERK1/pERK1, pMEK), EGFR/ERBB
(EGFR, HER2, HER3, HER4), IGF (IGFBP3, IGFBP5),
JAK/STAT (pSTAT3) and ERα (ESR1/pESR1, PGR, AIB1)
pathways. Further details of protein targets are shown in
Table 1. Examples of stained images are illustrated in
Fig. 1. There were 41 unique proteins in the set, 8 of
which were in both native and phosphorylated forms and
8 only in phosphorylated form. Activated pathways would
feature increased expression of phosphorylated proteins,
usually coupled with a concurrent drop in expression of
the native form.
We have previously shown significant relative tumor
volume reduction within the period up to 14 days
after a single treatment in the platinum responsive
OV1002 and a minimal response in platinum resistant
HOX424 ovarian cancer xenograft models [29] (Fig. 2).
This same sample set was analysed for the above-
named proteins. Carboplatin was administered at
50 mg/kg and tumors collected on days 1, 2, 4, 7 and
14 after treatment. Over this time period, analysis of
the protein set identified 13 differentially expressed
protein forms (ESR1, βCatenin, Claudin 7, MET, Cyc-
lin B1, HER4, S6, pBRCA1, pERK, pCDK2, pCHK1,
pH2AX, pS6) in carboplatin treated OV1002 xeno-
grafts, of which 6 were phosphoproteins (Additional
file 3). Proteins were grouped by hierarchical cluster-
ing into 3 clusters (which we have identified as down-
regulated early, upregulated late, and upregulated
Table 2 Sources of antibodies and the dilutions used in this
study
Protein name Gene name Source Catalog No. Dilution
AIB1 NCOA3 BD Biosciences 61105 1 in 50
AKT1 AKT Cell Signaling Ab4685 1 in 200
pAKT AKT Cell Signaling 9271 1 in 50
BRCA1 BRCA1 Eurogentec 75460 1 in 70
pBRCA1 BRCA1 Cell Signaling 9009 1 in 25
CyclinB1 CCNB1 Epitomics 1495-1 1 in 50
CyclinD1 CCND1 Dako M3635 1 in 100
E-Cadherin CDH1 BD sciences 610181 1 in 1500
CDK2 CDK2 Cell Signaling 2546 1 in 100
pCDK2 CDK2 Cell Signaling 2561 1 in 1500
CDKN1A P21 Cell Signaling 2946 1 in 100
CDKN1B P27 Cell Signaling 2552 1 in 100
CLDN7 Claudin7 Abcam AB27487 1 in 200
B-Catenin CTNNB1 BD sciences 610153 1 in 500
pB-Catenin CTNNB1 Cell Signaling 9561 1 in 25
EGFR EGFR Invitrogen 28-0005 1 in 50
ERBB2 HER2 Dako A0485 1 in 400
ERBB3 HER3 Dako M7297 1 in 50
ERCC1 ERCC1 Labvision MS-671-P0 1 in 600
ER1 ESR1 Neomarkers RM-9101-S1 1 in 100
pER1 ESR1 Cell Signaling 2511 1 in 50
pH2AX H2AFX Cell Signaling 2577 1 in 50
HER2 HER2 Dako M7297 1 in 400
HER3 HER3 Cell Signaling 4754 1 in 50
HER4 HER4 Cell Signaling 4792 1 in 300
HIF1A HIF1a Cell Signaling 3176 1 in 25
IGFBP3 IGFBP3 Abcam Ab4248 1 in 100
IGFBP5 IGFBP5 Abcam Ab4255 1 in 50
MAPK1 ERK Cell Signaling 9107 1 in 250
pMEK MAP2K1 Cell Signaling 9154 1 in 400
MET MET Eurogentec 75551 1 in 400
pMET MET Eurogentec 65559 1 in 25
MLH1 MLH1 Leica NCL-L-MLH1 1 in 100
MSH2 MSH2 Invitrogen 33-7900 1 in 50
MSH6 MSH6 Leica NCL-L-MSH6 1 in 250
MYC MYC Eurogentec 75355 1 in 70
pNFKB NFKB1 Cell Signaling 3037 1 in 25
PAI SERPINE1 BD Sciences P612024 1 in 200
PgR PGR Dako 3569 1 in 50
PMS2 PMS2 Leica NCL-L-PMS2 1 in 250
pP53 TP53 Cell Signaling 9286 1 in 100
PTEN PTEN Cell Signaling 9559 1 in 200
pRB RB1 Cell Signaling 9308 1 in 50
Table 2 Sources of antibodies and the dilutions used in this
study (Continued)
S6 RPS6 Cell Signaling 2217 1 in 100
pS6 RPS6 Cell Signaling 2211 1 in 200
SERPINE1 PAI BD Sciences P612024 1 in 200
SNAIL SNAI1 Abcam Ab17732 1 in 800
pSTAT3 STAT3 Cell Signaling 9145 1 in 25
Vimentin VIM Sigma V6630 1 in 400
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overall, corresponding to their dynamic changes) and
a singleton (ESR1 - which was downregulated)
(Fig. 3a). Differential expression was mostly late and
transient (Fig. 4). Native S6 was reduced early and
substituted by its late expressed phosphorylated form
(pS6) over time. pCDK2, pERK, pBRCA1 were upreg-
ulated at late time points, while expression of their
unphosphorylated counterparts was not significantly
changed (Fig. 5). Phosphorylated pH2AX was differen-
tially expressed at all five time points, while pCHK1
only at day 14.
In contrast to the increased phosphoprotein expres-
sion in treated xenografts, a range of unphosphorylated
protein expression responses was observed. Expression
of HER4, S6 and ER was inhibited one day post treat-
ment, while MET, βCatenin, Claudin7 and CyclinB1
were upregulated late (Fig. 5). Four of these proteins
were found differentially expressed also in the gene level:
CDK2, Cyclin B1, CHK1 and MET [29].
The HOX424 response to treatment was very limited.
Only one protein (MLH1) was differentially expressed in
carboplatin-treated xenografts (Additional file 3).
This minimal response is consistent with the very
limited tumor growth response to carboplatin
(Additional file 3).
Carboplatin-paclitaxel dynamically trigger a broader and
stronger phosphoprotein expression in ovarian cancer
xenografts
The combined carboplatin-paclitaxel treatment triggered
a more extensive response than carboplatin alone in the
OV1002 model. In contrast to only 13 proteins showing
differential expression with carboplatin, a total of 23
proteins (25 protein forms) (EGFR, HER4, PTEN, PAI,
Cyclin B1, pBRCA1, CTNNB1, MET, pAKT, Claudin 7,
ERK, pCTNNB1, pERK, p21, HER2, MYC, pH2AX,
pNFκB, pCHK1, SNAIL, pHH3, pSTAT3, pCDK2, pS6,
ESR1) were differentially expressed at both early and late
time points, of which 11 were phosphoproteins (Figs. 4
and 5, Additional file 3). These were clustered by
hierarchical clustering into 4 groups (identified as upreg-
ulated late, upregulated overall, downregulated early,
down- early/upregulated late) and a singleton (ESR1 -
downregulated) (Fig. 3b). Differentially expressed
proteins included all but one (S6) that were found
significant after carboplatin only treatment. Longitudinal
expression profiles between treatments were similar,
especially among phosphoproteins. Some distinct
expression patterns were observed after carboplatin-
paclitaxel treatment. Expression of pBRCA1 was in-
creased immediately after treatment (day 1), while
Fig. 1 Stained tissue images for AQUA quantitative image analysis. Representative immunofluorescence images of examples of the
phosphoproteins or total proteins used within the study. Blue = DAPI nuclear counterstain, Green = cytokeratin tumor mask, Red = target
protein. Formaldehyde fixed paraffin-embedded xenograft tissue was stained and analysed as described in Methods
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pCHK1 had a higher log fold change across all time
points compared to carboplatin only treatment. Five
additional phosphoproteins were differentially expressed
only after combined treatment. Expression of pAKT and
pNFκB were triggered shortly after treatment (day 1),
followed by pSTAT3 and pHH3 which were differentially
expressed from day 2. Phospho-βCatenin was expressed
late, from 7 days after treatment (Fig. 5). Expression of
four phosphoproteins was changed at least 2-fold:
pH2AX, pCHK1, pCDK2 and pBRCA1 (Fig. 5).
In contrast to carboplatin only treatment, early HER4
and ERα down-regulation were followed by up-regulation
at late time points after combination treatment. Addition-
ally, up-regulation of Cyclin B1 and Claudin 7 started
immediately after treatment. Another eight proteins were
differentially expressed after carboplatin-paclitaxel treat-
ment. Expression of PAI and PTEN was inhibited at day 2.
Expression of HER2 and MYC was upregulated at day 1
only, while EGFR and ERK were upregulated late. Snail
and p21 were upregulated at early and late time points
(Fig. 4). CDK2, Cyclin B1, BRCA1, CHK1, ESR1, HH3 and
STAT3 were differentially expressed in the corresponding
treatment to control comparison in the gene expression
study [29]. All were upregulated in both gene and protein
level, except the last two which were downregulated in the
gene level and positively regulated in the protein level.
Protein expression of HH3 and STAT3 was assessed only
in the phosphorylated form and this may explain the
discrepancy in expression between gene and protein.
The HOX424 response to combination treatment, as
with carboplatin alone treatment, was very limited. Only
two proteins (ESR1 and pMET) were differentially
expressed in carboplatin-paclitaxel treated xenografts
(Additional file 3). Again this is consistent with the very
minimal growth response shown to these drugs (Fig. 2).
Discussion
In this study, we characterised a dynamic protein re-
sponse to chemotherapy in two ovarian cancer models
over a period of 14 days using a set of protein markers
of pathways that are frequently deregulated in cancer
and may be associated with survival. Complementing an
earlier gene expression study, we found multiple pro-
teins differentially expressed after treatment in either or
both their native and phosphorylated forms allowing as-
sessment of relative expression of each form over time.
An increase of the activated (phosphorylated) forms was
observed indicating the activation of several pathways in
response to treatment. Certain proteins showed late
change in expression, detected here due to the relatively
prolonged period of expression monitoring (14 days).
There is potential to collect serial samples during treat-
ment of ovarian cancer, e.g., during neoadjuvant therapy
which is being increasingly considered prior to surgery
[35] or during adjuvant therapy by studying peritoneal
ascitic cells removed from patients before and after
therapy. Measurement of the dynamic markers identified
within this study could provide further information to
aid in the assessment of whether the tumor is sensitive
to treatment or not.
We observed distinct responses to treatment in each
cell line xenograft model. The serous derived OV1002
xenograft was highly responsive to carboplatin-based
treatment as judged by a decrease in RTV and marked
differential protein expression analysis. Differential pro-
tein expression in the slow growing and mainly unre-
sponsive clear cell/endometrioid derived HOX424 was
very limited after treatment, while the drop in RTV was
smaller in duration and magnitude. This observation
coincided with the post-treatment differential expression
pattern of these models at the gene level [29]. Correl-
ation of gene and protein expression was higher when
both were differentially expressed [36]. These results
suggest that responses to treatment among ovarian
cancer models of distinct histological origin vary which
is consistent with clinical experience. Testing more
Fig. 2 Relative Tumor Volume graphs. Post-treatment tumor volume
growth relative to day of treatment (Day 0) for the OV1002 (a) and
HOX424 (b) xenografts. (Carbo: Carboplatin; Taxane: Paclitaxel).
Modified from [29]
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models of diverse origin would be valuable in helping to
assess the range of responses to treatment in ovarian
cancer.
Carboplatin treatment in the platinum-sensitive
OV1002 model triggered up-regulation of cell cycle
(Cyclin B1, pCDK2, pCHK1), mTOR (S6, pS6) and DRR
(pH2AX, pBRCA1, pCHK1) pathways, while at late
time points WNT (βCatenin), invasion (Claudin 7),
EMT (c-MET) and MAPK (pERK) pathways were
modulated. Estrogen receptor-alpha (ESR1) and ERBB
(HER4) pathways were down-regulated early, within
24 h, as was S6. The early increase in pH2AX at
Fig. 3 Hierarchical clustering of post-treatment dynamic phosphoprotein expression. Heatmaps illustrating clusters of proteins with differentially
increased (red) or decreased (green) expression in response to carboplatin (a) or carboplatin-paclitaxel (b) treatment in OV1002 xenografts
Fig. 4 Differential expression analysis of treated OV1002 xenografts. Venn diagrams of differentially expressed protein form counts in each time
point (a) and according to their temporal characteristics (b) in carboplatin and carboplatin-paclitaxel treated OV1002 xenografts. Protein expression
was analysed in 5 time points post treatment (Days 1, 2, 4, 7 and 14). Early (late) genes were differentially expressed in Days 1, 2 and 4 (Days 7 and 14).
Transient (sustained) were differentially expressed in a single time point (more than one time points)
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Fig. 5 Post-treatment dynamic phosphoprotein/native protein differential expression graphs. Mean log fold differential expression of phosphoproteins (orange)/native proteins (red) in treated
OV1002 xenografts as compared to untreated controls. Proteins are significantly expressed in at least one time point. Corresponding gene expression from [29] (GEO accession number GSE49577)
is shown in blue where available, and its correlation to protein expression is indicated
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24 h was maintained through to Day 7 after which it
fell. Cell cycle changes (pCDK2, Cyclin B1) increased
progressively over the first 7 days and at the latest
time point indicators of WNT, EMT, Invasion and
MAPK pathways were increased. The changes in
DNA damage response and repair proteins and in cell
cycle associated proteins are in line with the DNA
lesions produced by carboplatin and consistent with
its mode of action [37]. In platinum-sensitive ovarian
cancer cells in vitro, we have previously shown that
markers of DDR such as pBRCA1 and p H2AX are
known to be induced over a 3–4 day period compar-
able to that seen in vivo [38]. The changes observed
in the current study are also consistent with differen-
tial expression patterns observed in the gene expres-
sion study, where several cell cycle and DDR proteins
used here were significant (Fig. 5). These variations
were anticipated and match the changes in tumor
volume after treatment.
Phosphorylation of H2AX on Ser139 is consistent with
formation of DNA strand breaks [39], while BRCA1 is
phosphorylated by ATM in response to double-stranded
DNA breaks [40]. CHK1 Ser 317 phosphorylation is then
consistent with checkpoint activation [41]. βCatenin has
been proposed as a target in this disease and may be
associated with chemoresistance [18]. Claudin 7 is
frequently overexpressed in ovarian cancer and has
been linked to increased migration [42]. High expres-
sion of c-MET in ovarian cancer has been associated
with poor survival and the use of c-MET inhibitors
could enhance the effects of platinum-taxane therapy
[43, 44]. The early changes in ESR1 and HER4 were
unexpected as were the later changes in invasion and
EMT proteins. High expression of ESR1 has been as-
sociated with outcome for ovarian cancer after
platinum-based therapy [45] and also decreased on
carboplatin treatment. Expression of HER4 (ERBB4)
has been associated with chemoresistance [46] in
ovarian cancer and this decreased on carboplatin
treatment. Several of the later changes may reflect
rapid regrowth, for example the increases in pERK
and pAKT. These proteins are key in activation of
their corresponding ERK and AKT pathways which
are complex, interacting cascades playing key roles in
normal and malignant cell growth [47].
Further responses were observed when carboplatin-
paclitaxel combination therapy was compared with
carboplatin treatment alone. The dynamic response to
the carboplatin-paclitaxel combination involved similar
or greater responses in the same pathways but with
more proteins demonstrating a response while additional
pathway molecules were also modulated (Fig. 6). There-
fore the cell cycle (Cyclin B1, pCDK2, pCHK1 and also
pHH3, MYC and p21) and DDR (pH2AX, pBRCA1,
pCHK1) pathways showed similar or more pronounced
changes than with carboplatin alone and with more of
the tested proteins demonstrating changed expression.
Consistent to our findings, p21 (CDKN1A) is reported
to increase after paclitaxel treatment in ovarian cancer
cells contributing to cell cycle regulation [48]. In
Fig. 6 Heatmap of post-treatment dynamic pathway activation in OV1002 xenografts. The number of differentially expressed (DE) protein members
of a pathway (Jak/STAT signaling, ERBB signaling, ERα signaling, mTOR signaling, WNT signaling, cell cycle, DDR, EMT/Invasion, MAPK signaling and AKT
signaling) in each time point is colour coded in shades of blue, for each treatment: carboplatin and carboplatin-paclitaxel
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addition to the mTOR molecule pS6 increasing, compo-
nents of the AKT pathway (pAKT, PTEN) were modu-
lated with pAKT increasing, while its tumor suppressor
regulator PTEN was down-regulated early on. The
MAPK pathway was again modulated with pERK expres-
sion increasing. WNT signaling (both βCatenin and
phospho-βCatenin), EMT markers (MET, SNAI1), inva-
sion (Claudin 7 and PAI) were again modulated gener-
ally at later time points. Increased SNAI1 expression has
been reported to relate to paclitaxel resistance in this
disease [49]. Additional pathways were also observed
with the NFκB (pNFκB) and JAK/STAT (pSTAT3)
pathways being up-regulated. NFκB has been shown to
possess a biphasic role in ovarian cancer [50] while
paclitaxel treatment of ovarian cancer cells has been
reported to activate the STAT3 pathway [51]. The ER-α
pathway was again down-regulated as was HER4, how-
ever further protein members of the ERBB pathway,
EGFR and HER2, were also upregulated late. HER2
expression has been reported to relate to paclitaxel
sensitivity in ovarian cancer cells in vitro [52]. These
findings are consistent with observations from the gene
expression study where several of the proteins used here,
mostly within the cell cycle and DDR functional groups,
were differentially expressed (Fig. 5).
Conclusion
The signaling changes induced by carboplatin and
carboplatin-paclitaxel indicate pathways activated by
the cytotoxic agents and may suggest new targets for
therapeutic intervention and potential ways to en-
hance chemotherapy effects. The changed expression
also provides predictive biomarkers of response. If
such dynamic changes can be identified in clinical
samples during treatment, they may help indicate the
responsiveness of the tumor to chemotherapy. Early
changes included DDR and cell cycle regulatory pro-
teins associating with tumor volume changes, which
were expected. Therefore inhibitors of the cell cycle
or the DDR signaling pathway, e.g., CHK inhibitors
[53], may merit further testing and assessment.
Changes in ESR1 and HER signaling were also ob-
served, as were late changes in EMT and invasion
markers, and these require further investigation to as-
sess their generality.
Availability of supporting data
All protein expression values analysed here are available
as Additional file 1 (Protein expression matrix). Add-
itionally, calculated log fold change values of differen-
tially expressed proteins for each condition are available
as Additional file 3 (Differential protein expression).
Gene expression values shown in Fig. 5 are taken from
[29] and are available from the Gene Expression Omnibus
(GEO) with accession number GSE49577 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49577).
Additional files
Additional file 1: Protein expression matrix. Protein expression matrix
of raw data of 49 proteins/phosphoproteins assayed in 166 xenograft
samples of the dataset. (XLSX 224 kb)
Additional file 2: Assessment of biological replicate concordance.
Number of replicates for all tested conditions (xenograft/treatment/day)
is shown. Correlation coefficients were calculated for all possible pairs of
biological replicates and averaged (mean replicate r) using expression
values from all detected proteins within each condition. (XLSX 42 kb)
Additional file 3: Differential protein expression. Log fold changes of
differentially expressed proteins over 14 days are shown in 4 worksheets,
each for a xenograft-treatment condition: carboplatin treated OV1002;
carboplatin treated HOX424; carboplatin-paclitaxel treated OV1002;
carboplatin-paclitaxel treated HOX424. (XLS 57 kb)
Abbreviations
AQUA: automated quantitative analysis; DDR: DNA damage response;
EMT: epithelial to mesenchymal; RTV: relative tumor volume.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AK and SPL wrote the manuscript and AK performed all computational
analyses. SPL, IU, KEF and CK performed all biological experiments. VAS, SPL
and DJH conceived the study. All authors read and commented on the
manuscript and agreed upon a final version together.
Acknowledgements
The authors thank Medical Research Scotland and the Scottish Funding
Council.
This work was supported by Medical Research Scotland [FRG353 to V.A.S.];
the FP7-Directorate-General for Research and Innovation of the European
Commission [EU HEALTH-F4-2012-305033 to Coordinating Action Systems
Medicine - D.J.H.]; the Chief Scientist Office of Scotland [D.J.H.], the Scottish
Funding Council [D.J.H. and S.P.L.]. Health Canada Scholarship (Indspire)
[KEF], Scottish Overseas Research Student Award Scheme (University of
Edinburgh)[KEF] and the Three Fires Award (Wikwemikong Board of
Education)[KEF].
Author details
1School of Biology, Sir Harold Mitchell Building, University of St Andrews, St
Andrews, Fife KY16 9TH, UK. 2Division of Pathology, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh, UK. 3School of
Medicine, University of St Andrews, St Andrews, UK.
Received: 31 August 2015 Accepted: 24 February 2016
References
1. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, et al. Systematic
review of first-line chemotherapy for newly diagnosed postoperative
patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol.
2002;85:71–80.
2. Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in
management. Eur J Cancer. 2002;38:1701–7.
3. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe,
1995–1999, and an overview of trends since 1960. Int J Cancer. 2004;110:
155–69.
4. Vogelstein B, Kinzler K. Cancer genes and the pathways they control. Nat
Med. 2004;10:789–99.
5. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse
somatic mutation patterns and pathway alterations in human cancers.
Nature. 2010;466:869–73.
Koussounadis et al. BMC Cancer  (2016) 16:205 Page 11 of 13
6. The Cancer Genome Atlas Research Network. Integrated genomic
analyses of ovarian carcinoma. Nature. 2011;474:609–15.
7. Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M,
et al. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br
J Cancer. 2009;101:1461–8.
8. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, et al. EGF/
ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247–58.
9. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in
cancer. Oncogene. 2007;26:3279–90.
10. Dobbin ZC, Landen CN. The importance of the PI3K/AKT/MTOR
pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14:
8213–27.
11. Barbolina MV, Burkhalter RJ, Stack MS. Diverse mechanisms for activation of WNT
signalling in the ovarian tumor microenvironment. Biochem J. 2011;437:1–12.
12. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene.
2000;19:2474–88.
13. Alvero AB. Recent insights into the role of NF-kappaB in ovarian
carcinogenesis. Genome Med. 2010;2:56.
14. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, Vizzielli G, et al.
Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical
outcome in advanced serous ovarian cancer. Gynecol Oncol. 2011;122:573–9.
15. Horiuchi A, Hayashi T, Kikuchi N, Hayashi A, Fuseya C, Shiozawa T, et al.
Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α
to a hypoxia-induced, methylation-free hypoxia response element of
S100A4 gene. Int J Cancer. 2012;131:1755–67.
16. Kim MK, Kim MA, Kim H, Kim YB, Song YS. Expression profiles of epithelial-
mesenchymal transition-associated proteins in epithelial ovarian carcinoma.
Biomed Res Int. 2014;2014:e495754.
17. Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, et al. MicroRNA-7 inhibits
tumor metastasis and reverses epithelial-mesenchymal transition through
AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.
PLoS One. 2014;9:e96718.
18. Arend RC, Londoño-Joshi AI, Straughn Jr JM, Buchsbaum DJ. The
WNT/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol.
2013;131:772–9.
19. Yazlovitskaya EM, Persons DL. Inhibition of cisplatin-induced ATR activity
and enhanced sensitivity to cisplatin. Anticancer Res. 2003;23:2275–9.
20. D’Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in
cisplatin-sensitive ovarian cancers. Cell Cycle. 2003;2:290–2.
21. Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA
damage. J Nucleic Acids. 2010;201367.
22. Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM. Pathway
analysis of gene lists associated with platinum-based chemotherapy
resistance in ovarian cancer: the big picture. Gynecol Oncol. 2010;117:170–6.
23. Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, et al.
Microarray-based oncogenic pathway profiling in advanced serous papillary
ovarian carcinoma. PLoS One. 2011;6:e22469.
24. Liu G, Yang D, Sun Y, Xue F, Sood AK, Zhang W. Differing clinical impact of
BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics.
2012;13:1523–35.
25. Faratian D, Um I, Wilson DS, Mullen P, Langdon SP, Harrison DJ.
Phosphoprotein pathway profiling of ovarian carcinoma for the
identification of potential new targets for therapy. Eur J Cancer.
2011;47:1420–31.
26. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, et al.
Functional proteomic analysis of advanced serous ovarian cancer using
reverse phase protein array: TGF-beta pathway signaling indicates response
to primary chemotherapy. Clin Cancer Res. 2010;16:2852–60.
27. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, et al.
A functional proteogenomic analysis of endometrioid and clear cell
carcinomas using reverse phase protein array and mutation analysis: protein
expression is histotype-specific and loss of ARID1A/BAF250a is associated
with AKT phosphorylation. BMC Cancer. 2014;14:120.
28. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic
pathway signatures in human cancers as a guide to targeted therapies.
Nature. 2006;439:353–7.
29. Koussounadis A, Langdon SP, Harrison DJ, Smith VA. Chemotherapy-
induced dynamic gene expression changes in vivo are prognostic in
ovarian cancer. Br J Cancer. 2014;110:2975–84.
30. Creixell P, Reimand J, Haider S, Wu G, Shibata T, Vazquez M, et al. Pathway
and network analysis of cancer genomes. Nat Methods. 2015;12:615-21.
31. Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, et al.
Trastuzumab and pertuzumab produce changes in morphology and
estrogen receptor signaling in ovarian cancer xenografts revealing new
treatment strategies. Clin Cancer Res. 2011;17:4451–61.
32. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and
quantification of protein expression in tissue microarrays. Nat Med.
2002;8:1323–8.
33. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A.
1998;95:14863–8.
34. Smyth GK. Limma: linear models for microarray data. In: Gentleman RRW,
Carey V, Dudoit S, Irizarry R, Huber WRW, editors. Bioinformatics and
Computational Biology Solutions Using R and Bioconductor. New York:
Springer; 2005. p. 397–420.
35. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a
personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol.
2015;12:239–45.
36. Koussounadis A, Langdon SP, Um I, Harrison DJ, Smith VA. Differential gene
expression has meaning: gene and protein expression correlate better
across experimental manipulation for differentially expressed genes. Sci Rep.
2015;5:10775.
37. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular
mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.
38. Huang R, Langdon SP, Tse M, Mullen P, Um IH, Faratian D, et al. The role of
HDAC2 in chromatin remodelling and response to chemotherapy in ovarian
cancer. Oncotarget. 2015;7:4695–711.
39. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-
stranded breaks induce histone H2AX phosphorylation on serine 139.
J Biol Chem. 1998;273:5858–68.
40. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent
phosphorylation of brca1 in the DNA damage response to double-strand
breaks. Science. 1999;286:1162–6.
41. Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. Specific role of
Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell
Biol. 2007;27:2572–81.
42. Dahiya N, Becker KG, Wood 3rd WH, Zhang Y, Morin PJ. Claudin-7 is
frequently overexpressed in ovarian cancer and promotes invasion. PLoS
One. 2011;6:e22119.
43. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR,
et al. c-Met overexpression is a prognostic factor in ovarian cancer and
an effective target for inhibition of peritoneal dissemination and
invasion. Cancer Res. 2007;67:1670–9.
44. Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, et al.
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel
to inhibit ovarian cancer cell growth. Oncol Rep. 2013;2:2011–8.
45. Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F. Oestrogen
receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated
with neo-adjuvant chemotherapy: determination by array and kinetic PCR in
fresh tissue biopsies. Endocr Relat Cancer. 2009;16:1241–9.
46. Gilmour LM, Macleod KG, McCaig A, Gullick WJ, Smyth JF, Langdon SP.
Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian
cancer. Cancer Res. 2001;6:2169–76.
47. Steelman LS, Chappell WH, Abrams SL, Kempf CR, Long J, Laidler P, et al.
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling
growth and sensitivity to therapy-implications for cancer and aging. Aging
(Albany NY). 2011;3:192–222.
48. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa
JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays
a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin
and paclitaxel. Cancer Res. 2000;60:5390–4.
49. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode
RY, et al. Snail and slug mediate radioresistance and chemoresistance by
antagonizing p53 mediated apoptosis and acquiring a stem-like phenotype
in ovarian cancer cells. Stem Cells. 2009;27:2059–68.
50. Yang G, Xiao X, Rosen DG, Cheng X, Wu X, Chang B, et al. The biphasic role
of NF-kappaB in progression and chemoresistance of ovarian cancer.
Clin Cancer Res. 2011;17:2181–94.
51. Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, et al.
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss
of cancer stem cell-like characteristics and a reduced tumor burden.
BMC Cancer. 2014;14:317.
Koussounadis et al. BMC Cancer  (2016) 16:205 Page 12 of 13
52. Aigner A, Hsieh SS, Malerczyk C, Czubayko F. Reversal of HER-2 over-
expression renders human ovarian cancer cells highly resistant to taxol.
Toxicology. 2000;144:221–8.
53. McNeely S, Beckmann R, Bence Lin AK. CHEK again: revisiting the
development of CHK1 inhibitors for cancer therapy. Pharmacol Ther. 2014;
142:1–10.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Koussounadis et al. BMC Cancer  (2016) 16:205 Page 13 of 13
